NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEMDRI (plazomicin) is an intravenous aminoglycoside antibiotic approved in 2018 for complicated urinary tract infections in patients with end-stage renal disease. The drug is administered as an IV solution and represents a niche therapeutic option for a specific renal disease population requiring parenteral antibiotic therapy.
Peak6.1 years to LOE
Product is in peak lifecycle stage but operates in a narrow niche market with zero competitive pressure, suggesting a stable, specialized team focused on maintaining renal disease specialist relationships.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Plazomicin Study in ESRD Patients Receiving IHD
Started Jan 2021
6 enrolled
End Stage Renal Disease
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Started Sep 2014
69 enrolled
Bloodstream Infections (BSI) Due to CREHospital-Acquired Bacterial Pneumonia (HABP) Due to CREVentilator-Associated Bacterial Pneumonia (VABP) Due to CRE+2 more
Career Relevance
ZEMDRI offers a specialized career path in nephrology-focused pharmaceutical sales and medical affairs, with limited growth but stable positioning in a niche, low-competition market. Roles are concentrated in hospital-based and specialty renal care settings where direct relationships with nephrologists and dialysis centers drive revenue.
Worked on ZEMDRI at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.